The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection
People with type 2 diabetes mellitus (T2DM) are at high risk of developing cardiovascular disease (CVD) and kidney disease. This enhanced cardio-renal risk persists despite improvements in care and treatments over the last 20 years. Intensive glucose control alone does not substantially reduce the r...
| Κύριος συγγραφέας: | |
|---|---|
| Μορφή: | Άρθρο |
| Γλώσσα: | Russian |
| Έκδοση: |
«FIRMA «SILICEA» LLC
2021-04-01
|
| Σειρά: | Российский кардиологический журнал |
| Θέματα: | |
| Διαθέσιμο Online: | https://russjcardiol.elpub.ru/jour/article/view/4323 |